ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0847 • ACR Convergence 2020

    Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity

    Laurence Magder1, Daniel Goldman2 and Michelle Petri2, 1University of Maryland, Baltimore, Baltimore, MD, 2Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
  • Abstract Number: 0865 • ACR Convergence 2020

    Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study

    Daniel J Wallace1, Thomas Dörner2, David Pisetsky3, F Jorge Sanchez-Guerrero4, Amy Kao5, Dana Parsons-Rich5, Anand Patel6, Yulia Zima5, Claire Le Bolay7, Karthinathan Thangavelu6 and Maria Dall'Era8, 1Cedars-Sinai Medical Center, Beverly Hills, CA, 2DRFZ and Charité University Hospitals, Berlin, Germany, 3Duke University Medical Center, Durham, NC, 4University Health Network/Sinai Health system, Toronto, ON, Canada, 5EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 6EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, 7Merck KGaA, Darmstadt, Germany, 8Division of Rheumatology, University of California, San Francisco, CA

    Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in signalling pathways known to be important to the pathogenesis of systemic lupus erythematosus (SLE). Evobrutinib is a…
  • Abstract Number: 0982 • ACR Convergence 2020

    Genetics of Avascular Necrosis in Children and Adults with Systemic Lupus Erythematosus

    Declan Webber1, JingJing Cao2, Daniela Dominguez3, Dafna Gladman4, Andrea Knight5, Deborah Levy1, Lawrence Ng6, Andrew Paterson2, Zahi Touma7, Murray Urowitz8, Joan Wither9, Earl D. Silverman10 and Linda Hiraki11, 1Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, 3Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, 4Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 5Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, 7University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, 8University Health Network, University of Toronto, Toronto, ON, Canada, 9University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 10Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, 11Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada

    Background/Purpose: Genetics have been shown to contribute to risk of avascular necrosis (AVN), a debilitating complication of systemic lupus erythematosus (SLE). Our aim was to…
  • Abstract Number: 1025 • ACR Convergence 2020

    Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades

    Ali Duarte-Garcia1, Mehmet Hocaoglu2, Shirley-Ann Osei-Onomah3, Jesse Dabit1, Sara J. Achenbach3 and Cynthia Crowson4, 1Mayo Clinic, Rochester, MN, 2University of Maryland Medical Center Midtown Campus, Baltimore, MD, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Prevalence estimates of disease are important for public health planning. The available prevalence estimates of systemic lupus erythematosus (SLE) do not account for changes…
  • Abstract Number: 1263 • ACR Convergence 2020

    Association of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and Damage Accrual in Long Standing Systemic Lupus Erythematosus

    Kaitlin Lima1, Alexandra Legge2, John Hanly2, Jungwha Lee3, Jing Song3, Anh Chung3 and Rosalind Ramsey-Goldman4, 1Northwestern University, Chicago, IL, 2Dalhousie University, Halifax, NS, Canada, 3Northwestern University, Chicago, 4Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) was recently shown to predict mortality and damage accrual in the SLICC inception cohort. The…
  • Abstract Number: 1279 • ACR Convergence 2020

    Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital

    Andrea Briones-Figueroa1, María Jesús García-Villanueva2, África Andreu Suárez1, Marina Tortosa-Cabañas2, Ana Corral-Bote2, Sandra Garrote-Corral2, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Madrid, Spain

    Background/Purpose: Data about incidence, clinical characteristics and outcome of patients with Systemic Lupus Erythematosus (SLE) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease is…
  • Abstract Number: 1295 • ACR Convergence 2020

    Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self-Assessments Based on Smart System of Disease Management (SSDM) Mobile Tools

    Yongfu Wang1, Hua Wei2, Rui Wu3, Jianhong Wu4, Shengtao Zhang5, Qin Li6, Yang Li7, You Sun7, Yanping Zhao8, Qiang Shu9, Lirong Kang1, Bin Wu10, Li Qin11, Feng Jiang11, Huiqin Yang12, Junli Zhang13, Hui Xiao14, Bing Wu15, Yuhua Jia15, Fei Xiao15 and Lingyun Sun16, 1The First Affiliated Hospital of BaoTou Medical College, Inner Mongolia University of Science and Technology, Baotou, China (People's Republic), 2Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), 3The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 4Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), 5Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (People's Republic), 6The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), 7The Second Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), 8First Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), 9Qilu Hospital of Shandong University, Jinan, China (People's Republic), 10The First People's Hospital of Jingzhou, Jingzhou, China (People's Republic), 11The No.3 People’s Hospital of HuZhou City, Huzhou, China (People's Republic), 12Wuhan No. 1 Hospital, Wuhan, China (People's Republic), 13Xi'an No. 5 Hospital, Xi'an, China (People's Republic), 14Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), 15Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), 16Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China (People's Republic)

    Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…
  • Abstract Number: 1499 • ACR Convergence 2020

    The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry

    Megan Clowse1, Jing Li2, Amanda Eudy3, Mehret Birru Talabi4 and Gabriela Schmajuk5, 1Duke University, Chapel Hill, NC, 2University of California, San Francisco, San Francisco, CA, 3Duke University, Durham, NC, 4University of Pittsburgh, Pittsburgh, PA, 5University of California, San Francisco, Atherton, CA

    Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
  • Abstract Number: 1621 • ACR Convergence 2020

    Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care

    Mehret Birru Talabi1, Kwonho Jeong1, Kaleab Abebe1, Megan Clowse2, Robyn Domsic3 and Sonya Borrero1, 1University of Pittsburgh, Pittsburgh, PA, 2Duke University, Chapel Hill, NC, 3University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Cervical cancer screening is important for women with systemic lupus erythematosus (SLE) and women prescribed TNF-alpha inhibitors (TNFi), as they have an increased risk…
  • Abstract Number: 1681 • ACR Convergence 2020

    Hemophagocytic Lymphohistiocytosis (HLH) Gene Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)

    Piya Lahiry1, Sergey Naumenko2, Fangming Liao3, Daniela Dominguez4, Andrea Knight5, Deborah Levy6, Melissa Misztal7, Lawrence Ng8, Earl D. Silverman9 and Linda Hiraki10, 1Hospital for Sick Children, Toronto, ON, Canada, 2The Centre for Computational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, 3Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, 4Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, 5Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 7Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Oakville, ON, Canada, 8Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, 9Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, 10Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada

    Background/Purpose: Familial Hemophagocytic lymphohistiocytosis (fHLH) is an autosomal recessive, hyper-inflammatory, life-threatening disease. Macrophage activation syndrome (MAS) is also known as secondary HLH due to the…
  • Abstract Number: 1793 • ACR Convergence 2020

    Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership

    Kristina Deonaraine1, Philip Carlucci1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21New York University, New York, NY

    Background/Purpose: Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and affects ~60% of patients during the course of their disease, leading…
  • Abstract Number: 1810 • ACR Convergence 2020

    Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine

    Anne Margrethe Troldborg1, Annette Hansen2, Kristian Stengaard-Pedersen2 and Steffen Thiel2, 1Aarhus University Hospital, Arhus, Denmark, 2Aarhus University, Aarhus, Denmark

    Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…
  • Abstract Number: 1827 • ACR Convergence 2020

    Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials

    Richard Furie1, Eric Morand2, Anca Askanase3, Ed Vital4, Joan Merrill5, Rubana Kalyani6, Gabriel Abreu7, Lilia Pineda6 and Raj Tummala6, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, 2Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 3Columbia University College of Physicians and Surgeons, New York, 4University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Oklahoma Medical Research Foundation, Oklahoma City, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…
  • Abstract Number: 1845 • ACR Convergence 2020

    Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study

    Dario Roccatello1, Savino Sciascia2, Roberta Fenoglio2 and Rossi Daniela2, 1S Giovanni Hospital, Univ of Turin, Turin, Italy, 2University of Torino, Torino, Italy

    Background/Purpose: Targeting B-cells remains an attractive option in Lupus Nephritis (LN) despite the negative results of RCTs.Methods: Sixty patients with active LN were included in…
  • Abstract Number: 170 • 2020 Pediatric Rheumatology Symposium

    Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE

    Nicole Bitencourt1, Justin Kramer 2, Bonnie Bermas 3, Elizabeth Solow 2, Tracey Wright 2 and Una Makris 2, 1UT Southwestern Medical Center, Dallas, Texas, 2UT Southwestern Medical Center, Dallas, 3UTSouthwestern Medical Center, Dallas

    Background/Purpose: The transition from pediatric to adult care for youth with chronic disease is known to be a vulnerable period, with adverse outcomes described for…
  • « Previous Page
  • 1
  • …
  • 158
  • 159
  • 160
  • 161
  • 162
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology